Related Experiment Video
Updated: May 13, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Evolving therapeutic targets in renal cell carcinoma
Eric A Singer1, Gopal N Gupta, Daniel Marchalik
1Section of Urologic Oncology, The Cancer Institute of New Jersey and UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Current Opinion in Oncology
|March 5, 2013
Summary
Recent advancements in advanced renal cell carcinoma (RCC) treatment focus on targeted therapies and combination strategies. Further research is needed to optimize drug selection and sequencing for specific kidney cancer subtypes.
Area of Science:
- Oncology
- Genitourinary Cancer
- Medical Genetics
Background:
- Advanced renal cell carcinoma (RCC) treatment landscape is evolving with new targeted agents.
- Understanding the molecular and genetic basis of RCC subtypes is crucial for personalized medicine.
Purpose of the Study:
- To review recent developments in advanced RCC treatment, focusing on data from the past year.
- To discuss the genetics and molecular biology of kidney cancer subtypes for rational drug development.
Main Methods:
- Review of recent scientific literature on advanced renal cell carcinoma (RCC) treatment.
- Analysis of genomic and metabolic alterations in various kidney cancer histologic subtypes.
Main Results:
- Targeting vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways remains foundational for metastatic kidney cancer.
- Emphasis on target selectivity and affinity to reduce toxicity in clear cell RCC.
- Combination strategies and histology-specific protocols for nonclear cell RCC are under investigation, with no specific drug approvals yet.
Conclusions:
- The number of approved treatments for advanced RCC is increasing.
- Further research is required to determine optimal drug choices, combinations, and sequences for each RCC subtype.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...